Showing posts with label against. Show all posts
Showing posts with label against. Show all posts

Friday, January 27, 2012

LGV cases almost triple in one year; UK public health officials warn against serosorting

The number of gay men infected with the sexually transmitted infection lymphogranuloma venereum (LGV) has almost tripled in one year, and the UK now has the world’s worst epidemic of LGV, the Health Protection Agency reported today. At the same time, the agency is tracking an outbreak in gay men of shigellosis, a bacterial infection that is transmitted through contact with tiny amounts of human faeces.

The HPA suspects that transmission of both infections is being fuelled by serosorting behaviour, in other words men choosing to have unprotected sex with men who have the same HIV status as themselves. While HIV-positive men who serosort may avoid passing on their HIV infection, they still risk acquiring unpleasant and often serious sexually transmitted infections such as LGV, shigella and hepatitis C. Serosorting “is unsafe”, the HPA says.

LGV is a previously rare sexually transmitted infection, seen in UK gay men since 2003. It is caused by specific strains of Chlamydia. If left untreated, symptoms can be complex and severe, including proctitis (inflammation of the anus or rectum).

Diagnoses of LGV increased from 190 in 2009 to 530 in 2010. Of the total 1560 cases seen between 2003 and 2010, more than one third have been diagnosed since the beginning of 2010.

The vast majority (83%) of LGV cases were in HIV-positive gay men. The infection is thought to be transmissible during unprotected anal intercourse, an activity which 84% of infected men report. Two-thirds of diagnoses were in London, but there are cases from across the country, especially Brighton and Manchester.

The public health agency is also concerned about a smaller outbreak of shigellosis. This bacterial infection, caused by either Shigella sonnei or Shigella flexneri has only occasionally been seen in UK gay men. The symptoms of shigellosis can include severe and bloody diarrhoea, but it can be successfully treated with antibiotics.

Shigella is transmitted by contact with tiny amounts of faeces. This can occur as a consequence of poor hygiene, or may be linked to sex, especially rimming, fingering, fisting, anal sex, and handling used sex toys and douching equipment. The bacteria may pass from dirty fingers to the mouth; basic hygiene and handwashing habits reduce the risk of transmission.

There have been 29 cases of infection with Shigella flexneri recorded since May 2011, mostly in London or Manchester. The HPA have not yet identified the key characteristics of the men who have been infected or identified the shared use of specific venues. However some previous shigellosis outbreaks have been concentrated in men with HIV and in men who used sex-on-premises venues.

The HPA report also notes the ongoing epidemic of sexually acquired hepatitis C in gay and bisexual men with HIV - 228 cases of recent infection were recorded at 22 of the larger HIV clinics in 2008-2010.

In addition, new diagnoses of the more widespread infections chlamydia and gonorrhoea are higher than they have been for more than a decade, at around 4500 and 5000 diagnoses respectively.

The HPA believes these figures highlight the dangers for HIV-positive men of ‘serosorting’, in other words having unprotected sex with partners thought also to be HIV-positive. “Serosorting poses a risk of acquiring other STIs and hepatitis, with serious treatment implications,” the agency warns.

It does not encourage HIV-negative men to serosort either, because rates of undiagnosed HIV are high. One quarter of those infected do not know that they have HIV.


View the original article here

Sunday, January 22, 2012

New vaccine against pneumococcal disease approved for UK

 A new vaccine that may be more suitable for preventing pneumococcal disease in people living with HIV has been approved in the United Kingdom.

Prevenar 13, manufactured by Pfizer, is targeted at 13 variants of Streptococcus pneumoniae.

Recently published research carried out by the Health Protection Agency shows that among people with HIV, these variants cropped up in 61% of cases of invasive pneumococcal disease diagnosed in 2009. In contrast the PCV7 vaccine would have protected against only 23% of cases.

The Health Protection Agency research also showed that the incidence of invasive pneumococcal disease was 20 times higher among people with HIV compared with the general population.

Illness caused by Streptococcus pneumoniae is a common cause of ill health in the general population. In most people it causes mild health problems such as sinusitis and chest infections, but more severe cases of penumococcal disease can result in septicaemia, severe pneumonia or meningitis.

Tthe risk of invasive and potentially life-threatening pneumococcal disease is higher in the over-50s and in people with suppressed immunity, chronic respiratory conditions such as asthma, heart, liver or kidney disease.

The Prevenar 13 vaccine has been licensed for use in adults aged 50 years and over.

Current UK vaccination policy is to offer the PPV-23 vaccine to adults aged 65 and over, and to adults in specified risk groups, including people living with HIV. The Joint Committee on Vaccination and Immunisations (JCVI) concluded in March 2011, on the basis of unpublished data provided by manufacturer Pfizer, that “there is no conclusive evidence that [the PCV-13] vaccine would be more effective in older adults”.

The JCVI made no specific recommendation regarding vaccination for people living with HIV, despite an initial recommendation from the JCVI’s Pneumococcal sub-committee that people with HIV with controlled viraemia should receive two doses of the PVC-13 vaccine followed by one dose of the PPV-23 vaccine.

2008 guidance from the British HIV Association recommended use of the PPV-23 vaccine in people living with HIV with CD4 cell counts above 200 cells/mm3, and that it should be considered for those with CD4 counts below 200. This recommendation was framed in the light of evidence of lower vaccine efficacy in people with CD4 counts below 200.

The British HIV Association's Immunisation Comittee plans new guidance in 2012 with a view to recommending the PCV-13 vaccine, Dr Anna-Maria Geretti of London's Royal Free and University College Medical School told aidsmap.

The PCV-13 is already licensed for use in children and is used routinely in the UK childhood vaccination programme.


View the original article here

The Hot Boys Sexpert

The Hot Boys World News

Google Reader

POZ HIV/AIDS News and Information

Fight HIV in DC Event Calendar

AIDSmeds HIV/AIDS Treatment News

THBWorld Sexpert Archive